Weight-loss drugs have become a high-stakes global opportunity, and now a major Indian pharma player is stepping into the obesity fight with a fresh drug development. The move signals intensifying competition as companies chase demand for effective treatments, where speed to scale, manufacturing reach, and clinical promise could decide who leads the next wave of obesity medicines worldwide.
India’s weight-loss drug market is rapidly shifting as generic semaglutide becomes available after Novo Nordisk’s patent loss. The cheaper alternatives are already pressuring Eli Lilly’s sales while unlocking a surge in demand. With multiple Indian drugmakers racing to launch affordable options, the country’s obesity-treatment landscape is entering a new, more price-accessible phase.
Your news, in seconds
Get the Beige app — every story in 60 words, updated hourly. Free on iOS & Android.
India’s obesity treatment market is expected to change quickly by year-end as oral GLP1 weight-loss pills become widely available, including new options from China. These tablet therapies promise a cheaper, easier alternative to injectable GLP1 drugs, which could boost patient adoption as convenience and affordability rise. Market analysts expect demand to accelerate as more people can access treatment.
Retatrutide, an investigational weight-loss drug, is drawing global attention after early clinical results showed substantial weight reduction. What makes it stand out is its “triple-action” approach, targeting three hormone receptors involved in metabolism. Researchers are also exploring whether it could support broader longevity goals, potentially offering new options for obesity and related diabetes.
Swipe through stories, personalise your feed, and save articles for later — all on the app.
